Switching To or From Oral Micronized Progesterone (Prometrium): Protocols, Timing, and Clinical Evidence

How Oral Micronized Progesterone Works

OMP is bioidentical progesterone, meaning its molecular structure is identical to the progesterone produced by the human corpus luteum. After oral ingestion, it undergoes first-pass hepatic metabolism and binds the progesterone receptor (PR) in the endometrium, inducing secretory transformation that opposes estrogen-driven proliferation 1. This is the same receptor-level action as synthetic progestins, but with a different downstream metabolite profile.

The micronization process reduces particle size to 10 microns or smaller, suspended in peanut oil, which increases gastrointestinal absorption by roughly 10-fold compared to non-micronized progesterone 2. Peak serum concentrations reach approximately 17 to 38 ng/mL within 2 to 3 hours of a 200 mg oral dose. The elimination half-life is short, roughly 16 to 18 hours, which is why nightly dosing is standard.

A key metabolite, 5-alpha-pregnanolone (allopregnanolone), acts as a positive allosteric modulator at GABA-A receptors. This accounts for the sedative effect that many patients report and is the reason clinicians prescribe OMP at bedtime 3. Synthetic progestins like MPA do not produce allopregnanolone in meaningful quantities, so the sedation profile is unique to OMP and can be either a benefit or a nuisance depending on the patient.

Unlike MPA, OMP does not bind the androgen receptor or the glucocorticoid receptor with clinically significant affinity 4. This selectivity explains why switching from a synthetic progestin to OMP often resolves complaints of bloating, mood changes, and acne that patients attribute to androgenic or glucocorticoid crosstalk.

Why Clinicians Switch Patients to OMP

The most common reason is side-effect intolerance on a synthetic progestin. MPA, the most widely prescribed synthetic, was associated with a statistically significant reduction in HDL cholesterol in the PEPI Trial (N=875), while the OMP arm maintained HDL levels comparable to the estrogen-only group 1. That finding alone changed prescribing habits for many clinicians.

Breast tissue density is another driver. A French E3N cohort study (N=80,377) found that women using estrogen plus synthetic progestins had a relative risk of breast cancer of 1.69 (95% CI 1.50 to 1.91), while those using estrogen plus micronized progesterone showed no statistically significant increase (RR 1.00 to 95% CI 0.83 to 1.22) over a mean follow-up of 8.1 years 5. The 2022 North American Menopause Society (NAMS) position statement noted that "micronized progesterone and dydrogesterone may be associated with lower breast cancer risk than synthetic progestins" 6.

Mood disturbance on MPA is a third reason. A randomized crossover trial by Fitzpatrick et al. found that women who reported depressive symptoms on MPA experienced significant mood improvement after switching to OMP 200 mg cyclic, with a mean Beck Depression Inventory score reduction of 4.2 points (P=0.03) 7.

Some patients also switch in the opposite direction, from OMP to a synthetic. This is less common but occurs when the sedation from allopregnanolone is excessive, when peanut allergy precludes Prometrium use, or when breakthrough bleeding persists despite adequate OMP dosing.

Switching From MPA (Provera) to OMP

This is the most frequently executed progestogen switch in clinical HRT practice. No washout period is required. The conversion is straightforward.

For patients on continuous combined therapy (MPA 2.5 mg daily), the standard substitution is OMP 100 mg nightly. Some clinicians use 200 mg nightly for the first 3 months if the patient has risk factors for endometrial hyperplasia or if prior ultrasound showed endometrial thickness greater than 4 mm 8.

For patients on cyclic MPA (5 mg or 10 mg for 12 to 14 days per month), the substitution is OMP 200 mg nightly for 12 to 14 days. The switch can happen at the start of the next progestin phase. Withdrawal bleeding patterns may change during the first 2 to 3 cycles; patients should be counseled that this is expected and does not indicate endometrial pathology.

The PEPI Trial provides the strongest direct comparison data. Over 36 months, the cyclic OMP arm (200 mg for 12 days/month) had a rate of endometrial hyperplasia of 1%, compared to 0% in the continuous MPA arm and 34% in the unopposed estrogen arm 1. The difference between OMP and MPA was not statistically significant for endometrial protection, confirming therapeutic equivalence at these doses.

Dr. JoAnn Manson, principal investigator of the Women's Health Initiative, has stated: "Micronized progesterone offers a favorable safety profile compared with medroxyprogesterone acetate, particularly regarding cardiovascular and breast outcomes" 9.

Switching From Norethindrone Acetate (NETA) to OMP

NETA is the progestogen component in several combination HRT products, including Activella (estradiol/NETA 1 mg/0.5 mg) and femhrt. Switching requires separating the estrogen and progestogen components.

Step one: replace the combination product with standalone transdermal estradiol or oral estradiol at a bioequivalent dose. For Activella 1 mg/0.5 mg, the estradiol component is 1 mg oral, which roughly equates to a 0.05 mg/day transdermal patch 10.

Step two: add OMP 100 mg nightly (continuous) or 200 mg nightly for 12 days per cycle. Again, no washout is needed between stopping NETA and starting OMP. The progestogen switch can occur the same day.

NETA has notable androgenic activity. Patients switching to OMP frequently report resolution of acne, oily skin, and unwanted hair growth within 4 to 8 weeks 4. Conversely, patients who were benefiting from NETA's mild androgenic effects on libido may notice a decrease. This trade-off should be discussed before the switch.

Switching From OMP to a Levonorgestrel IUD (Mirena)

For patients who want to eliminate the oral progestogen entirely, the levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena 52 mg) provides local endometrial suppression while continuing systemic estrogen therapy. The FDA approved Mirena for endometrial protection during HRT in many countries, though in the United States the primary indication remains contraception 11.

The transition protocol is simple. Insert the LNG-IUS and continue OMP for one additional cycle (14 days) to ensure endometrial suppression while the device establishes therapeutic levonorgestrel concentrations locally. After that overlap cycle, OMP is discontinued.

A randomized trial by Varila et al. (N=40) demonstrated that the LNG-IUS suppressed endometrial proliferation as effectively as cyclic OMP 200 mg over 12 months, with 100% of LNG-IUS patients showing atrophic or inactive endometrium on biopsy versus 95% in the OMP group 11. The LNG-IUS group reported fewer episodes of withdrawal bleeding (0 vs. a mean of 10.2 episodes per year).

Switching From Dydrogesterone to OMP

Dydrogesterone (Duphaston) is a retro-isomer of progesterone used widely in Europe and Asia. It is not available in the United States. Patients relocating or seeking a bioidentical option may need to switch.

The dose equivalence is approximately dydrogesterone 10 mg to OMP 200 mg for cyclic regimens, based on comparative endometrial biopsy data from the PEPI-equivalent European studies 12. For continuous therapy, dydrogesterone 5 mg daily maps to OMP 100 mg nightly.

No washout is necessary. The switch is made at the start of the next progestin cycle or on the next calendar day for continuous regimens. Patients should be warned about the sedative effect of OMP, which dydrogesterone does not produce, and advised to take the capsule at bedtime.

Monitoring After a Progestogen Switch

Every progestogen switch warrants a follow-up plan. Bleeding patterns are the primary surveillance tool.

Unscheduled bleeding that persists beyond 3 months after any switch requires evaluation with transvaginal ultrasound and, if endometrial thickness exceeds 4 mm, endometrial biopsy 13. The 2022 NAMS position statement recommends that "any new bleeding pattern after a progestogen change should be evaluated if it does not stabilize within 3 to 6 months" 6.

Lipid panels should be repeated 3 months after switching from MPA to OMP to document the expected HDL improvement. In the PEPI Trial, the OMP group maintained a mean HDL increase of 4.1 mg/dL above baseline, while the MPA group showed a mean decrease of 2.4 mg/dL from their estrogen-only baseline 1.

Progesterone serum levels are not routinely measured for oral formulations because of wide inter-individual variation and rapid metabolism. If adherence is in question, a trough level drawn in the morning (12 to 14 hours after the evening dose) should be at least 2 ng/mL to suggest adequate absorption 14.

Compounded vs. FDA-Approved Micronized Progesterone

Patients sometimes ask about switching from Prometrium to a compounded progesterone capsule, or vice versa. This is not a benign substitution. Compounded oral progesterone capsules are not required to demonstrate bioequivalence to Prometrium, and independent assays have shown significant variability in potency, ranging from 59% to 137% of the labeled dose across compounding pharmacies 15.

The Endocrine Society's 2017 position statement on compounded bioidentical hormones stated: "There is no scientific basis for the claim that compounded bioidentical hormones are safer or more effective than FDA-approved formulations" 15. If a patient is switching from a compounded product to Prometrium, an endometrial assessment at the time of the switch is prudent to rule out subclinical hyperplasia from possible under-dosing.

Special Populations and Switching Considerations

Patients with peanut allergy cannot use Prometrium, which contains peanut oil. The FDA labeling carries a specific contraindication. These patients should use a synthetic progestin or the LNG-IUS for endometrial protection. A soy-based OMP formulation exists in some markets but is not FDA-approved in the United States.

Patients with hepatic impairment metabolize OMP more slowly, leading to higher and more prolonged serum concentrations and exaggerated sedation. For these patients, a switch from OMP to vaginal micronized progesterone (100 mg or 200 mg) bypasses first-pass metabolism and eliminates the allopregnanolone-mediated sedation while still providing endometrial protection 16. The REPLENISH Trial (N=1,845) validated vaginal progesterone for endometrial protection at the 100 mg dose over 12 months, with hyperplasia rates of <1% 16.

Patients on anticonvulsants (carbamazepine, phenytoin, phenobarbital) experience CYP3A4 induction that accelerates OMP clearance. Serum progesterone levels may fall below the threshold for endometrial protection. These patients may require a dose increase to 300 mg nightly or a switch to the LNG-IUS, which is not affected by hepatic enzyme induction 10.